FindTrial
Sign In

GTx-024

DRUG8 trials

Sponsors

GTx

Conditions

CachexiaER+ and AR+ Breast CancerMuscle WastingNon Small Cell Lung CancerNon-Small Cell Lung CancerStress Urinary IncontinenceTriple Negative Breast Cancer

Phase 2

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
CompletedNCT00467844
GTxCachexia
Start: 2007-05-31End: 2008-09-30Updated: 2014-07-11
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
TerminatedNCT02368691
GTxTriple Negative Breast Cancer
Start: 2015-06-30End: 2017-09-22Updated: 2020-11-18
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
CompletedNCT02463032
GTxER+ and AR+ Breast Cancer
Start: 2015-08-31End: 2019-03-31Updated: 2020-12-09
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
CompletedNCT02658448
GTxStress Urinary Incontinence
Start: 2016-01-31End: 2018-06-30Updated: 2021-02-01
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
WithdrawnNCT03508648
GTxStress Urinary Incontinence
Start: 2018-05-28End: 2018-09-21Updated: 2023-09-14
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
WithdrawnNCT03566290
GTxStress Urinary Incontinence
Start: 2018-06-28End: 2018-09-21Updated: 2024-03-01

Phase 3

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
CompletedNCT01355484
GTxMuscle Wasting, Non Small Cell Lung Cancer
Start: 2011-07-31End: 2014-06-30Updated: 2016-03-03
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
CompletedNCT01355497
GTxMuscle Wasting, Non-Small Cell Lung Cancer
Start: 2011-07-31End: 2014-06-30Updated: 2020-11-09

Related Papers

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
2024-02-0829 citations
Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
Cancer Research2022-02-152 citations
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
Journal of Clinical Oncology2021-05-2034 citations
The importance of body composition and physical function on overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy (PBCT).
Journal of Clinical Oncology2018-05-20
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
2016-06-01111 citations
Enobosarm and lean body mass in patients with non-small cell lung cancer.
Journal of Clinical Oncology2014-05-2019 citations
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
2013-03-14276 citations